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TURUN YLIOPISTO 
Lääketieteellinen tiedekunta 
TUOMAS KULJU: Association of smoking with activity of ankylosing spondylitis – 
systematic review and meta-analysis 
Syventävien opintojen kirjallinen työ, 15 s. 
Fysiatria 
Maaliskuu 2020 
Meta-analyysin tarkoitus oli selvittää kirjallisuusnäyttö tupakoinnin ja selkärankareuman 
aktiivisuuden yhteydestä mittaamalla eroa tupakoijien ja tupakoimattomien välillä Bath 
Ankylosing Spondylitis Disease Activity Index (BASDAI) -mittarilla. 
 
Tietolähteinä käytettiin Medlinea, Embasea, Scopusta sekä Web of Science -
tietokantoja, joista systemaattinen haku suoritettiin helmikuussa 2020. Artikkelit valittiin 
kahden itsenäisen ja riippumattoman arvioijan toimesta ja systemaattisen harhan riskiä 
arvioitiin NIH Quality Assessment Tool for Observational Cohort and Cross-Sectional 
Studies -työkalulla muokatusti. Tiedot haettiin ennaltamääritellyillä ehdoilla. 
 
Katsauksen aineistoon valittiin 18 artikkelia jotka kaikki käsittelivät 
poikkileikkausotantoja. Yhteenlaskettu otos koostui 3.599 tupakoijasta sekä 3.591 
tupakoimattomasta selkärankareumapotilaasta. Yksittäisten tutkimusten potilasmäärät 
vaihtelivat 18 ja 1.141 välillä, selkärankareumadiagnoosista kulunut aika myös vaihteli 
huomattavasti - kolmesta kahteenkymmeneen vuoteen. 
 
Meta-analyysissä BASDAI-pisteiden yhteenlaskettu painotettu keskiarvo oli 0,6 (95% 
luottamusväli 0,42 – 0,78) tupakoimattomien hyväksi. Ero oli tilastollisesti merkitsevä, 
mutta se jäi BASDAI-mittarin pienimmän kliinisesti merkittävän eron (0,8 pistettä) 
alapuolelle.  
 
Näyttöä kliinisesti merkittävästä korrelaatiosta tupakoinnin ja selkärankareuman 
aktiivisuuden välillä mitattuna BASDAI-pisteytyksellä ei ole löytynyt. 
 
Avainsanat: selkärankareuma, tupakointi  
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ABSTRACT 
Objective: To evaluate the evidence regarding the association of smoking and disease activity in patients 
with SA measured by difference between smokers and non-smokers in the BASDAI scores.  
Data sources: Medline, Embase, Scopus, and Web of Science databases were searched in February 2020. 
Study selection: The study selection was performed by two independent reviewers. The risk of systematic 
bias was assessed according to the NIH Quality Assessment Tool for Observational Cohort and Cross-
Sectional Studies. 
Data extraction: The data were extracted using a pre-defined standardized form.  
Results: The search resulted in 714 records. The final sample consisted of 18 papers with cross-sectional 
data. The sample sizes varied from 18 to 1,141. There was a substantial variation in the time since SA inset 
– from three up to 20 years. Most of the included studies reported better BASDAI scores for non-smokers. 
The pooled sample consisted of 3,599 smokers and 3,591 non-smokers. The sizes of smokers’ groups 
varied widely from 19 up to 1,141 patients. The pooled mean difference in BASDAI scores was 0.6 (95% CI 
0.42 to 0.78) points in favor of non-smokers. The pooled result fell below the level of minimal clinically 
important difference (MCID) for BASDAI of 0.8 points. There was a significant heterogeneity: Q=50.9 
(df=17) and I2=67%. 
Conclusions: Smoking seems to be associated with severity of SA only weakly and clinically insignificantly 
when measured by BASDAI. 
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INTRODUCTION 
Smoking is widely recognized as a risk factor for such connective tissue disorders as rheumatoid arthritis 
and systemic lupus erythematosus. It has been associated with disease activity and severity, response to 
therapy, and mortality rate by several reviews (Harrison 2002, Stolt, Bengtsson et al. 2003, Baka, Buzas et 
al. 2009, Onozaki 2009, Sugiyama, Nishimura et al. 2010, Klareskog, Malmstrom et al. 2011, Serra-Bonett 
and Rodriguez 2011, Chang, Yang et al. 2014, Lee, Bae et al. 2014, Jiang, Li et al. 2015, Anderson, Meyer 
et al. 2016, Speyer and Costenbader 2018, Vittecoq, Richard et al. 2018, Ishikawa and Terao 2020).  
The correlation between smoking and ankylosing spondylitis (SA) is less studied. Smoking has been 
reported to be associated with earlier SA onset, disease activity, deteriorated functioning and quality of 
life, more severe radiographic inflammatory and structural lesions (Wendling and Prati 2013, Villaverde-
Garcia, Cobo-Ibanez et al. 2017, Akar, Kaplan et al. 2018). That association may have a dose-dependent 
manner. The effects of smoking in SA may be related to the elevated level of inflammation, which is seen 
e.g. by a higher concentration of C-reactive protein, citrullinated vimentin, and metalloproteinases – a 
predictive factor for SA radiographic progression. Additionally, smoking may negatively affect 
bronchopulmonary and cardiovascular functions, which are already impaired by SA. Only a few reviews 
have previously focused on the effect of smoking in SA (Wendling and Prati 2013, Villaverde-Garcia, Cobo-
Ibanez et al. 2017, Akar, Kaplan et al. 2018). Of them, one review was narrative (Wendling and Prati 2013) 
and only one review employed meta-analysis focusing on radiographic outcomes (Akar, Kaplan et al. 
2018). A single previous systematic review has concentrated on clinically measured effects of smoking in 
SA. That review has suggested that smoking is associated with more severe pain, worse general health 
status, disease activity, physical immobility, and poorer quality of life (Villaverde-Garcia, Cobo-Ibanez et 
al. 2017). That review did not include a meta-analysis and graded the level of evidence as poor expressing 
also concern on inability to separate the effect of smoking from confounding factors. Thus, there is a lack 
of systematically evaluated evidence on the association of smoking with SA activity. 
Several approaches have been introduced to assess the activity of SA (Garrett, Jenkinson et al. 1994), the 
Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) being amongst the most validated and reliable 
scales (Madsen, Rytter et al. 2010). The BASDAI is often considered to be a golden standard for the task. 
The objective of this systematic review was to evaluate the evidence regarding the association of smoking 
and disease activity in patients with SA measured by difference between smokers and non-smokers in the 
BASDAI scores. 
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METHODS 
Inclusion and exclusion criteria (PICO) 
• Population: Adults with ankylosing spondylitis. Excluded: spondylitis related to other conditions 
e.g. other connective tissue disorders, Crohn disease etc. Patients were considered as smokers if 
they were current or previous smokers. 
• Papers: Any design. Papers published in academic peer-reviewed journals, English language, 
abstract available. Excluded: theses, conference proceedings, case reports etc. 
• Exposure: smoking defined as smoking in present or in the past regardless of duration or quantity  
• Comparison: non-smoking status defined as never smoked. 
• Outcome: difference between groups in disease activity measured by the BASDAI scale. 
The initial intention was to include a wider variety of outcome measures such as changes in radiological 
progression, disease activity, function, and quality of life. However, this approach had to be abandoned 
after the selection based on full texts: there were 43 papers on the subject employing great spectrum of 
different and mostly incomparable outcomes. At that point, the decision was made to proceed with 
difference between groups in disease activity measured by the BASDAI scale as a single outcome. 
Data sources 
Medline via PubMed, Embase, Scopus, and Web of Science. The search clause for the Medline search was: 
("smoking" [Mesh] OR smoking OR tobacco OR cigarette OR cigar OR smoker*) AND ("spondylitis, 
ankylosing"[Mesh] OR (ankylo*[TIAB]  AND spondyl* [TIAB]) OR bechterew* [TIAB] OR marie-struempell 
[TIAB] OR “rheumatoid spondylitis” [TIAB] OR spondylarthritis [TIAB] OR spondyloarthritis [TIAB]) NOT 
(Review[ptyp] OR review [TI]) AND (hasabstract[text] AND English[lang]) 
In order to avoid missing potentially relevant studies, the use of other limiters and filters was restricted 
and the authors relied instead on manual selection. Similar clauses were used when searching the other 
databases. The references of identified articles and reviews were also checked for relevance. 
Selection strategy 
The records identified from the data sources were stored using Endnote software (Endnote X7.8, Thomson 
Reuters). Using a build-in search engine of the Endnote software, duplicates, conference proceedings, 
theses, reviews, and case reports were deleted. Two independent reviewers screened the titles and 
abstracts of the remaining articles and assessed the full texts of potentially relevant papers (Figure 1). 
Disagreements between the reviewers were resolved by consensus or by a third reviewer. 
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Extraction strategy 
The data needed for a quantitative assessment were extracted using a standardized form based on 
recommendations by the Cochrane Handbook for Systematic Reviews of Interventions (Higgins and Green 
2011). The form included: a first author name, a year of publication, a country, a sample, a gender 
distribution, the average age of patients, the duration of follow-up, and the estimates of main outcomes. 
Assessment of the methodological risks of systematic bias  
Two independent reviewers rated the risk of systematic bias using four criteria adopted from the NIH 
Quality Assessment Tool for Observational Cohort and Cross-Sectional Studies (NIH 2020).  The 
assessment was based on the clarity of research question and study population, a power analysis, and the 
clarity of definition of smoking status. The risk of bias was dichotomized as “yes” vs. “no”. Disagreements 
between the reviewers were resolved by consensus or by a third reviewer.  
Main outcome measure – BASDAI 
The BASDAI scale consists of six items: fatigue, spinal pain, arthralgia, enthesites (areas of localized 
tenderness where connective tissues insert into bone), and the duration and severity of morning stiffness. 
The items are rated on a Likert-like scale from zero to 10. The scores obtained for the duration and severity 
of morning stiffness are pooled into one score. The total score is a sum of five individual scores divided by 
five resulting in a possible range from zero (least activity) to 10 (most activity) points. Using a distribution-
based method (appropriate for cross-sectional design used here by all of the included studies), the 
minimal clinically important difference (MCID) for BASDAI has previously been estimated around 0.8 
points (van Tubergen, Black et al. 2015). 
Statistical analysis (meta-analysis) 
A random-effects model was used to quantify the pooled effect size of the included studies, which was a 
more fitting choice than a fixed-effect model considering the context of medical decisions making and 
generalizing the results beyond the selected samples. The results were presented as raw mean differences 
and accompanied by 95% confidence intervals (95% CIs). The heterogeneity was tested using the Q test 
and I² statistic. Heterogeneity was deemed present if Q was greater than the degree of freedom (number 
of studies – 1). The I² statistic described the percentage of the variability in effect estimates that is due to 
heterogeneity rather than sampling error (chance). The potential publication bias was assessed using the 
Egger’s test (two-tailed p-value considered significant if =<0.05), and trim-and-fill correction was applied 
if needed. All calculations were performed using the Comprehensive Meta-Analysis CMA software, 
Version 3.0, available from www.meta-analysis.com. 
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RESULTS 
The search resulted in 714 records (Figure 1). Of them, 103 records were assessed based on their titles 
and abstracts and 46 were assessed based on the full texts. The final sample consisted of 18 papers (Kaan 
and Ferda 2005, Reed, Dharmage et al. 2008, Mattey, Dawson et al. 2011, Chung, Machado et al. 2012, 
Chen, Chen et al. 2013, Fallahi, Jamshidi et al. 2013, Poddubnyy, Haibel et al. 2013, Gaber, Hassen et al. 
2015, Ramiro, Landewe et al. 2015, Sakellariou, Anastasilakis et al. 2015, Zhang, Li et al. 2015, Jones, Ratz 
et al. 2017, Zhao, Challoner et al. 2017, Dülger, Karlıbel et al. 2018, Zhang, Wan et al. 2018, Dülger, Aykurt 
Karlibel et al. 2019, Karlibel, Dulger et al. 2019, Zhao, Jones et al. 2019). All of them reported cross-
sectional data on smoking status and the BASDAI scores. The sample sizes varied from 18 to 1,141 and 
samples were predominated by male patients (Table 1). The average age varied from 30 up to 50 years. 
There was a substantial variation in the time since SA inset – from three up to 20 years. The most common 
source of the risk of systematic bias was absent study power analysis (Table 2). As smoking has often been 
a secondary outcome, the research question regarding smoking was clearly defined in half of the studies.  
Most of the included studies reported better BASDAI scores for non-smokers although only eight studies 
resulted in clinically significant differences between groups (Figure 2).  The pooled sample consisted of 
3,599 smokers and 3,591 non-smokers. The sizes of smokers’ groups varied widely from 19 up to 1,141 
patients. The pooled mean difference in BASDAI scores was 0.6 (95% CI 0.42 to 0.78) points in favor of 
non-smokers. There was a significant heterogeneity – Q=50.9 (df=17). Of this heterogeneity, 67% (I2) was 
coming from the variation of true effect size. There was not a significant risk of publication bias – Egger’s 
p-value 0.77 without a need for a trim-and-fill correction.  
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DISCUSSION 
This systematic review evaluated the evidence on correlation between smoking and disease activity in SA. 
The meta-analysis of 18 cross-sectional studies showed statistically significant difference between ever-
smokers and never-smokers in activity level of SA measured by difference in the BASDAI scores. The 
difference fell, however, below the minimal clinically important difference of BASDAI. There was a 
substantial heterogeneity of the pooled effect. 
This was the first meta-analysis on association between smoking and disease activity measured by the 
BASDAI. The results of this meta-analysis should be interpreted with caution. Meta-analysis is always an 
approximation. All the included study samples were cross-sectional. Therefore, no certain causality could 
be established. There was substantial heterogeneity between the included studies. The dichotomization 
of exposure as ever-smoking vs. never-smoking left the effects of smoking amount and the length of 
smoking history unclear. While the BASDAI is a reliable validated scale, the activity of such a complex 
condition as SA can hardly be explained by a single outcome.  
The results of present review are in line with an earlier review, which has found evidence on only weak 
effect of smoking on pain level reporting correlation between current smoking and worse BASDAI scores 
in patients with SA (Villaverde-Garcia, Cobo-Ibanez et al. 2017). The present review was able to reveal this 
correlation in more details employing meta-analysis approach. Additionally, unlike previous reviews, the 
present study compared the pooled effect of smoking with the BASDAI MCID producing clinically 
interpretable results. Another review  has found evidence on correlation between smoking and 
cumulative structural damage in SA – smokers have had significantly more syndesmophytes than never-
smokers (Akar, Kaplan et al. 2018). That finding is incomparable with the results of present review, which 
left structural radiographic damage outside the scope.  
There is a need for longitudinal research to reveal the potential causality in association of smoking with 
SA activity. Further research on pathophysiologic and molecular models of smoking effect in SA may 
introduce a plausible hypothesis behind the possible effect of smoking on SA activity. Additional research 
may reveal the effects of dose-dependency, time of quitting of smoking and pack-years measured by 
BASDAI as well as other outcomes. 
Conclusions 
Smoking seems to be associated with severity of SA activity only weakly and clinically insignificantly when 
measured by using the BASDAI scale.   
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FIGURES AND TABLES 
Figure 1. Search flow 
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Figure 2. Forest plot of raw mean differences between smokers and non-smokers in disease activity 
measured by BASDAI scale. 
 
 
Study name Statistics for each study Sample size Difference in means and 95% CI
Difference Lower Upper Relative 
in means limit limit Smokers Non-smokers weight
Poddubnyy 2013 -0.38 -1.00 0.24 71 139 5
Dulger 2019 -0.30 -1.37 0.77 40 31 2
Karlibel 2019 -0.10 -1.23 1.03 47 20 2
Dulger 2018 0.00 -1.00 1.00 54 38 3
Ramiro 2015 0.20 -0.55 0.95 49 78 4
Chung 2012 0.30 -0.02 0.62 241 413 9
Zhang 2018 0.42 0.18 0.66 410 768 10
Chen 2013 0.46 -0.46 1.38 35 40 3
Reed 2008 0.51 -0.21 1.23 58 68 4
Sakellariou 2015 0.60 -0.40 1.60 84 22 3
Zhang 2015 0.60 0.18 1.02 307 118 7
Fallahi 2013 0.61 0.52 0.70 47 113 12
Jones 2017 0.80 0.42 1.18 562 384 8
Mattey 2011 1.00 0.53 1.47 298 308 7
Zhao 2019 1.11 0.85 1.37 1141 890 10
Zhao 2017 1.15 0.34 1.96 112 126 4
Gaber 2015 1.40 0.24 2.56 19 11 2
Kaan 2005 1.44 0.80 2.08 24 24 5
0.60 0.42 0.78 3599 3591
-3.00 -1.50 0.00 1.50 3.00
<-- Disease less active Disease more active -->
Meta Analysis
Meta Analysis
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Table 1. Characteristics of the included studies 
Study, year 
Smokers Non-smokers Time since 
onset, years n Women Age n Women Age 
Chen 2013 35 0% 35 40 0% 32 11 
Chung 2012 241 49% 31a 413 57% 33 a 1.5 
Dülger 2018 40 28% 37 31 16% 38 4 
Dülger 2019 54 17% 38 38 39% 40 11 
Fallahi 2013 61 n/r b 38 99 n/r b 38 14.5 
Gaber 2015 19 0% 29 11 0% 35 7.5 
Jones 2017 562 25% 53 384 29% 51 16 
Kaan 2005 24 50% 35 24 50% 35 3 
Karlibel 2019 47 0% 33 20 0% 40 10 
Kau 2017 77 1% 39 137 38% 40 8 
Mattey 2011 298 n/r b 49 308 n/r b 49 15 
Poddubnyy 2013 71 42% 34 139 53% 39 4 
Ramiro 2015 49 18% 38 78 37% 42 20 
Reed 2008 22 n/r b 45 104 n/r b 45 20 
Sakellariou 2015 84 6% 42 22 6% 42 15.5 
Zhang 2015 118 18% 29 307 18% 29 7.5 
Zhang 2018 410 2% 37 768 63% 37 7.5 
Zhao 2017 112 17% 46 126 31% 46 5 
Zhao 2019 1141 29% 49 890 37% 48 20 
a At onset; b Not reported 
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Table 2. Risk of systematic bias in the selected studies. 
Study and 
outcome 
Research question and 
objective clearly stated 
Study population 
clearly defined 
Sample size 
justified 
Smoking status 
clearly defined 
Chen 2013 Yes Yes No Yes 
Chung 2012 Yes Yes No No 
Dülger 2018 Yes No No Yes 
Dülger 2019 Yes Yes No Yes 
Fallahi 2013 Yes Yes No Yes 
Gaber 2015 No No No Yes 
Jones 2017 No Yes No Yes 
Kaan 2005 No No No No 
Karlibel 2019 No No No Yes 
Mattey 2011 Yes Yes No Yes 
Poddubnyy 2013 Yes Yes No Yes 
Ramiro 2015 No Yes No No 
Reed 2008 No Yes No No 
Sakellariou 2015 Yes Yes No Yes 
Zhang 2015 No No No Yes 
Zhang 2018 No No No Yes 
Zhao 2017 No No No Yes 
Zhao 2019 Yes Yes No Yes 
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